In Retrospect: Root-Cause Analysis of Structure-Activity Relationships in IRAK4 Inhibitor Zimlovisertib (PF-06650833).
Wright, S.W., Farley, K.A., Han, S., Knafels, J.D., Lee, K.L.(2024) ACS Med Chem Lett 15: 540-545
- PubMed: 38628800 
- DOI: https://doi.org/10.1021/acsmedchemlett.4c00036
- Primary Citation of Related Structures:  
8W3W, 8W3X - PubMed Abstract: 
In this paper, we disclose insights on the root causes of three structure-activity relationship (SAR) observations encountered in the discovery of the IRAK4 inhibitor Zimlovisertib (PF-06650833). The first is a nonlinear potency SAR encountered with the isoquinoline ether substituent, the second is a potency enhancement introduced by fluorine substitution on the lactam, and the third is a slight potency preference for all- syn (2 S ,3 S ,4 S ) stereochemistry in the fluorine-substituted lactam. We present new data that help to inform us of the origins of these unexpected SAR trends.
Organizational Affiliation: 
Medicine Design, Pfizer Inc., 445 Eastern Point Rd, Groton, Connecticut 06340, United States.